tiprankstipranks
Advertisement
Advertisement

NKTR Stock Latest News

NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Allegedly Concealed Trial Protocol Violations: Levi & Korsinsky
Class ActionNKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Allegedly Concealed Trial Protocol Violations: Levi & Korsinsky
2d ago
NKTR
Nektar Therapeutics Faces Investor Lawsuit Over Alleged Clinical Trial Enrollment Failures and Misleading Disclosures
PremiumClass Action
Nektar Therapeutics Faces Investor Lawsuit Over Alleged Clinical Trial Enrollment Failures and Misleading Disclosures
4d ago
NKTR
Nektar initiated with a Neutral at Wedbush
PremiumThe Fly
Nektar initiated with a Neutral at Wedbush
5d ago
NKTR
Nektar management to meet with BTIG
PremiumThe Fly
Nektar management to meet with BTIG
5d ago
NKTR
DraftKings, Eli Lilly downgraded: Wall Street’s top analyst calls
PremiumThe Fly
DraftKings, Eli Lilly downgraded: Wall Street’s top analyst calls
12d ago
LI
AJG
Nektar Therapeutics: Rezpeg Clinical Momentum and Strong Cash Runway Underscore Attractive Risk‑Reward at Current Levels
PremiumRatingsNektar Therapeutics: Rezpeg Clinical Momentum and Strong Cash Runway Underscore Attractive Risk‑Reward at Current Levels
12d ago
NKTR
Nektar initiated with a Buy at TD Cowen
Premium
The Fly
Nektar initiated with a Buy at TD Cowen
12d ago
NKTR
Buy Rating on Nektar Driven by Rezpeg’s Blockbuster Potential in Atopic Dermatitis and Alopecia Areata
Premium
Ratings
Buy Rating on Nektar Driven by Rezpeg’s Blockbuster Potential in Atopic Dermatitis and Alopecia Areata
12d ago
NKTR
Nektar price target raised to $123 from $102 at Citi
PremiumThe Fly
Nektar price target raised to $123 from $102 at Citi
13d ago
NKTR
Nektar Therapeutics Bets Big on Respag Phase 3
PremiumCompany Announcements
Nektar Therapeutics Bets Big on Respag Phase 3
15d ago
NKTR
Nektar price target raised to $140 from $115 at Oppenheimer
PremiumThe Fly
Nektar price target raised to $140 from $115 at Oppenheimer
15d ago
NKTR
Morning Movers: Adobe falls with Narayen set to exit as CEO
PremiumThe Fly
Morning Movers: Adobe falls with Narayen set to exit as CEO
16d ago
KLC
NIO
Closing Bell Movers: Adobe down 8% despite Q1 beat as CEO steps down
PremiumThe FlyClosing Bell Movers: Adobe down 8% despite Q1 beat as CEO steps down
16d ago
S
LEN
Nektar reports Q4 EPS ($1.78) vs. 52c last year
Premium
The Fly
Nektar reports Q4 EPS ($1.78) vs. 52c last year
16d ago
NKTR
Nektar options imply 5.9% move in share price post-earnings
Premium
The Fly
Nektar options imply 5.9% move in share price post-earnings
16d ago
NKTR
NKTR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
NKTR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
19d ago
NKTR
Nektar price target raised to $150 from $105 at B. Riley
PremiumThe Fly
Nektar price target raised to $150 from $105 at B. Riley
1M ago
NKTR
Nektar enters research collaboration for NKTR-0165 in multiple sclerosis
PremiumThe Fly
Nektar enters research collaboration for NKTR-0165 in multiple sclerosis
1M ago
NKTR
Nektar Therapeutics Prices Upsized Public Equity Offering
PremiumCompany Announcements
Nektar Therapeutics Prices Upsized Public Equity Offering
1M ago
8K
NKTR
Nektar 6.6M share Secondary priced at $58.00
PremiumThe FlyNektar 6.6M share Secondary priced at $58.00
1M ago
NKTR
2 Strong Buy Stocks with 90%+ Upside to Buy Now, According to Top Analysts, 2/11/2026
Premium
Market News
2 Strong Buy Stocks with 90%+ Upside to Buy Now, According to Top Analysts, 2/11/2026
2M ago
AMZN
BETA
Buy Rating on NKTR Driven by Rezpeg’s Strong Phase 2 Maintenance Data and Favorable Risk‑Reward in Atopic Dermatitis
Premium
Ratings
Buy Rating on NKTR Driven by Rezpeg’s Strong Phase 2 Maintenance Data and Favorable Risk‑Reward in Atopic Dermatitis
2M ago
NKTR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >